Axovant Announces Second Fiscal Quarter 2018 Financial Results and Corporate Updates
07 nov. 2018 16h05 HE
|
Axovant Sciences Ltd.
First patient dosed in clinical study of AXO-Lenti-PD, a novel gene therapy for treatment of Parkinson’s diseaseExpanded pipeline of gene therapies with in-licensing of AXO-AAV-OPMD for treatment of...
Axovant Announces Dosing of First Patient in Clinical Study of AXO-Lenti-PD, a Novel Gene Therapy for Patients With Parkinson’s Disease
25 oct. 2018 02h00 HE
|
Axovant Sciences Ltd.
Initial data from the first cohort expected in first half of 2019 BASEL, Switzerland, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON), a company developing innovative gene...
Axovant Announces Data to be Presented at the Annual Congress of the European Society of Gene and Cell Therapy
09 oct. 2018 09h02 HE
|
Axovant Sciences Ltd.
BASEL, Switzerland, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON), a gene therapy company developing innovative treatments for debilitating neurologic and neuromuscular diseases,...
Axovant to Present at Two Upcoming Investor Conferences
20 sept. 2018 07h00 HE
|
Axovant Sciences Ltd.
BASEL, Switzerland, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON) today announced that Pavan Cheruvu, M.D., chief executive officer, will present a corporate overview at the...
Axovant to Present at Upcoming Investor Conferences
29 août 2018 07h00 HE
|
Axovant Sciences Ltd.
BASEL, Switzerland, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ: AXON) today announced that Pavan Cheruvu, M.D., chief executive officer, will participate in two upcoming investor...
Axovant Announces First Fiscal Quarter 2018 Financial Results and Corporate Update
07 août 2018 16h05 HE
|
Axovant Sciences Ltd.
Pipeline expanded with gene therapy technologies including AXO-Lenti-PD for treatment of Parkinson’s Disease and AXO-AAV-OPMD for treatment of oculopharyngeal muscular dystrophy Ilise Lombardo, MD,...
Axovant Announces Global Licensing Agreement for AXO-AAV-OPMD Program for Treatment of Oculopharyngeal Muscular Dystrophy and Broader Platform Collaboration with Benitec Biopharma
08 juil. 2018 20h18 HE
|
Axovant Sciences Ltd.
License grants Axovant worldwide rights to AXO-AAV-OPMD utilizing proprietary Silence-and-Replace technology, which suppresses mutant protein production while restoring expression of functional...
Axovant to Present at First Annual Roivant Pipeline Day
18 juin 2018 08h30 HE
|
Axovant Sciences Ltd.
BASEL, Switzerland, June 18, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON) today announced that Pavan Cheruvu, M.D., chief executive officer, will present a corporate overview at the first...
Axovant Licenses Investigational Gene Therapy for Parkinson’s Disease from Oxford BioMedica and Announces Key Leadership Team Addition
06 juin 2018 02h00 HE
|
Axovant Sciences Ltd.
Exclusive worldwide license to lentiviral vector gene therapy constitutes the first transaction of Axovant’s 2018 pipeline expansionFraser Wright, Co-Founder and former Chief Technology Officer of...
Axovant to Present at Two Upcoming Investor Conferences
31 mai 2018 07h00 HE
|
Axovant Sciences Ltd.
BASEL, Switzerland, May 31, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON) today announced that Pavan Cheruvu, M.D., chief executive officer, will present a corporate overview at the...